DENVER, April 25, 2005 (PRIMEZONE) -- Medical International Technology, Inc. ("MIT") (OTCBB:MDIR) (http://www.mitcanada.ca), a developer and manufacturer of patented needle free jet injectors for human and animal inoculation, is pleased to announce that its needle free injector has been chosen for testing in a study regarding the treatment of Hyperhydrosis.
Prominent Dermatologist Begins BOTOX(r) Injections for Hyperhydrosis. Will Use MIT Needle Free Injector In The Process.
Dr. Antranik Benohanian MD, FRCPC, Dermatologist at Saint-Luc Hospital of The Montreal University Hospital Centre, has begun tests of MIT's human injectors in his Hyperhydrosis studies. In addition to the underarms, Hyperhydrosis often occurs in the palms, soles of the feet and even the face. To date, treatments have only carried out by needle injections that must be repeated every 4-6 months, resulting in severe pain to patients and leading to refusal of treatment by most patients who are reluctant to receive multiple injections in their hand and their face.
Using MIT's MedJet(r) MBX injector will significantly relieve patients of pain and discomfort in these sensitive areas of the body that is caused by traditional needle injections, as well as, lead to significantly fewer refusals of treatment. In addition, MIT's needle free injector results in a far less severe puncture since it has a volume of .02cc to .3cc. It is important to be able to increase or decrease the volume and pressure of injection, based on the comfort level of the patient. This technology is unique to MIT's MedJet(r) MBX Injector.
Hyperhydrosis is the medical term for excessive sweating. Millions of people worldwide suffer from this condition. In a recent study, an estimated 2.8% of the U.S. population is affected by some form of this condition, with about a third of them describing their excessive sweating as barely tolerable or worse. BOTOX(r) injections were approved by the FDA in July 2004 to treat severe Hyperhydrosis. Clinical studies show that 80% of patients experienced a 50% decrease in sweat production. These successful results make the introduction and use of needle free injectors even more critical to the process.
"We are extremely pleased that Dr. Benohanian has chosen MIT's MedJet(r) Needle Free MBX Model Injectors to test his BOTOX(r) treatments for Hyperhydrosis," stated Karim Menassa, President and CEO of Medical International. "We look forward to Dr. Benohanian's results and the hopeful proliferation of our products as the standard in treating Hyperhydrosis across World," added Mr. Menassa.
Results of the test will be released to MIT and will be published on Dr. Benohanian's website at http://benohanian.com/en/indexen.htm.
First Shipments to Hong Kong Delivered
Further to our Press Release of March 8, 2005, MIT has delivered 5 units of the 25 purchased by Winsor (Hong Kong). The remaining units will be delivered over the next few weeks.
This press release is available on the Medical International Investor Relation's site for investor questions, commentary and feedback. Investors are asked to visit http://www.agoracom.com/IR/MIT. Alternatively, investors can e-mail their questions or comments directly to MDIR@agoracom.com or asked to be placed on the Medical International investor e-mail list to receive all future press releases directly.
About Medical International Technology, Inc. (http://www.mitcanada.ca) MIT CANADA, with offices in Montreal, is a subsidiary of Denver, Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass vaccinations.
The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development and acquisition of new product lines and services, government approval processes, the impact of competitive products or pricing a technological changes, the effect of economic conditions and other uncertainties, and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. Medical International Technology, Inc. takes no obligation to update or correct forward-looking statements.